This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AbbVie Presents First Study Assessing The Role Of Predefined Doses Of Methotrexate When Used In Combination With HUMIRA® (adalimumab) For Rheumatoid Arthritis

MADRID, June 13, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the treatment of moderate to severe rheumatoid arthritis (RA). CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label HUMIRA®. Results were presented at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain.

The primary objective of CONCERTO was to determine a dose-response pattern of MTX in combination with HUMIRA® in MTX and biologic-naive patients with active moderate to severe RA for less than 1 year. Patients were randomized into four treatment arms, receiving 40 mg of open-label HUMIRA® every other week in combination with weekly oral MTX at 2.5 mg, 5 mg, 10 mg or 20 mg. For all four treatment groups, the primary endpoint was the achievement, at week 26, of low disease activity, defined by a Disease Activity Score 28 (DAS28) of <3.2. Percentages of patients achieving low disease activity were as follows:
  • 43 percent (n=98) of patients in the 2.5 mg per week MTX group;
  • 44 percent (n=100) of patients in the 5 mg per week MTX group;
  • 57 percent (n=99) of patients in the 10mg per week MTX group; and
  • 60 percent (n=98) of patients in the 20 mg per week MTX group (P<0.005 for the trend).

"In general, anti-tumor necrosis factor biologic medications, or anti-TNFs, need methotrexate to achieve better clinical and radiological outcomes versus these medications alone," said Gerd R. Burmester, M.D., Professor of Medicine, Department of Rheumatology and Clinical Immunology, Charite-University Medicine Berlin, Berlin, Germany. "The CONCERTO trial describes the extent to which the methotrexate dose affects clinical responses when implementing the combination therapy of adalimumab and methotrexate." AbbVie Inc. +1 (847) 938-9190 1 North Waukegan Road North Chicago, IL 60064

DAS28 measurement is a composite index that includes variables such as tender and swollen joint counts, a patient's visual analog scale for disease activity and C-reactive protein (CRP) as a measure of inflammation. CONCERTO was double-blind for the MTX dose and open-label for the use of HUMIRA®.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs